Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309
Recruiting · NCT05957081 · Registry updated 2025-12-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 | Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 | 2025-12-30 | NCT05957081 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| Novotech (Australia) Pty Limited | 15 |
| PharmAbcine | 1 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Alfred Health | Melbourne | Australia | 32 |
| Australian Hospital Care (Pindara) PTY LTD. Trading as Pindara Private Hospital | Benowa | Australia | 1 |
| Ballarat Regional Integrated Cancer Centre (Grampians Health) | Ballarat | Australia | 1 |
| Cabrini Health Limited | Malvern | Australia | 4 |